Patent intelligence · US
US 9006283
Methods of modifying amyloid β oligomers using non-peptidic compounds
Methods of modifying amyloid β oligomers using non-peptidic compounds
Patent details — US 9006283
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 14, 2015
- Expiration
- Apr 9, 2035
- Applicant
- Acumen Pharmaceuticals, Inc.
- Claims
- 7
- CPC classes
- A61K, A61K31/381, A61K31/41, A61K31/415
Quick answer
US 9006283 (Methods of modifying amyloid β oligomers using non-peptidic compounds) is held by Acumen Pharmaceuticals, Inc.. Status: granted. Granted Apr 14, 2015. Expires Apr 9, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Acumen Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K31/381, A61K31/41, A61K31/415, A61K9/0019, A61K9/0075
More from Acumen Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 9320793
Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
granted -
US 9217024
ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
granted -
US 8962677
Methods of restoring cognitive ability using non-peptidic compounds
granted -
US 8507206
Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta)
granted -
US 7964359
Compositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance
granted
Frequently asked questions
What is US patent 9006283?
US 9006283 (Methods of modifying amyloid β oligomers using non-peptidic compounds) is held by Acumen Pharmaceuticals, Inc.. Status: granted. Granted Apr 14, 2015. Expires Apr 9, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9006283?
Acumen Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 9006283 expire?
Our index shows an expiration date of Apr 9, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.